Abstract
Pancreatic cancer is digestive cancer with limited therapeutic options and a poor outcome. Pancreatic cancer has a high mortality rate, with a 5-year survival rate of less than 5%. The median survival after metastasis of the disease is less than 6 months. Studies have revealed that the standard treatment, including palliative chemotherapy or immunotherapy, is not significantly effective for pancreatic cancer. Herein, we report a case of pancreatic cancer who benefited from a combination of anti-PD-1 immunotherapy and chemotherapy.
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
MeSH terms
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Agents, Immunological
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Biomarkers, Tumor
-
Fluorouracil
-
Humans
-
Immune Checkpoint Inhibitors / administration & dosage
-
Immune Checkpoint Inhibitors / adverse effects
-
Immune Checkpoint Inhibitors / therapeutic use*
-
Irinotecan
-
Leucovorin
-
Male
-
Middle Aged
-
Oxaliplatin
-
Pancreatic Neoplasms / drug therapy*
-
Pancreatic Neoplasms / surgery
Substances
-
Antineoplastic Agents
-
Antineoplastic Agents, Immunological
-
Biomarkers, Tumor
-
Immune Checkpoint Inhibitors
-
folfirinox
-
Oxaliplatin
-
Irinotecan
-
Leucovorin
-
Fluorouracil